Compare · STVN vs SYK
STVN vs SYK
Side-by-side comparison of Stevanato Group S.p.A. (STVN) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STVN and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $112.48B, about 21.4x STVN ($5.26B).
- SYK has been more active in the news (7 items in the past 4 weeks vs 2 for STVN).
- SYK has more recent analyst coverage (25 ratings vs 24 for STVN).
- Company
- Stevanato Group S.p.A.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $5.26B
- $112.48B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2021
- News (4w)
- 2
- 7
- Recent ratings
- 24
- 25
Stevanato Group S.p.A.
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest STVN
- Deutsche Bank initiated coverage on Stevanato Group S.p.A.
- Officer Stocchi Mauro sold $293,454 worth of Ordinary Shares (13,649 units at $21.50), decreasing direct ownership by 3% to 400,000 units (SEC Form 4)
- UBS initiated coverage on Stevanato Group S.p.A.
- Stevanato Group to Participate in Two Upcoming Investor Conferences
- SEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.
- Director Magistretti Elisabetta sold $41,084 worth of Ordinary Shares (2,045 units at $20.09), decreasing direct ownership by 41% to 2,930 units (SEC Form 4) to cover taxes
- Chief Financial Officer Dal Lago Marco sold $84,559 worth of Ordinary Shares (4,209 units at $20.09), decreasing direct ownership by 5% to 81,144 units (SEC Form 4) to cover withholding tax
- Director Santel Luciano sold $40,642 worth of Ordinary Shares (2,023 units at $20.09), decreasing direct ownership by 30% to 4,739 units (SEC Form 4) (withholding tax)
- SEC Form 6-K filed by Stevanato Group S.p.A.
- SEC Form 6-K filed by Stevanato Group S.p.A.
Latest SYK
- Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
- Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
- Barclays initiated coverage on Stryker with a new price target
- SEC Form 8-K filed by Stryker Corporation
- Stryker announces leadership succession
- Stryker to announce third quarter 2026 financial results
- VP, Chief Financial Officer Wells Preston Wendell disposed of 109 shares, decreasing direct ownership by 3% to 3,661 units (SEC Form 4)
- VP, Chief Financial Officer Wells Preston Wendell disposed of 2,739 shares, decreasing direct ownership by 42% to 3,770 units (SEC Form 4)
- Stryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
- New insider Baculik Emily Kay claimed ownership of 1,554 shares (SEC Form 3)